TickerFacts.

Burning Rock Biotech Ltd (BNR): Cost of Revenue

Annual figures by period end, from SEC filings.

136.65M CNY
Year ended 2025-12-31
-9.3%
3-year compound annual growth
+3.3%
5-year compound annual growth
183.20M CNY2018-12-31: 73.81M CNY2019-12-31: 108.34M CNY2020-12-31: 115.98M CNY2021-12-31: 143.72M CNY2022-12-31: 183.20M CNY2023-12-31: 174.21M CNY2024-12-31: 153.42M CNY2025-12-31: 136.65M CNY136.65M CNY
2018-12-31 Cost of Revenue (CNY) 2025-12-31
Period endedCost of RevenueChange YoYSource filing
2025-12-31136.65M CNY-10.9%2026-04-28, From 2025-01-01
2024-12-31153.42M CNY-11.9%2026-04-28, From 2024-01-01
2023-12-31174.21M CNY-4.9%2026-04-28, From 2023-01-01
2022-12-31183.20M CNY+27.5%2025-04-29, From 2022-01-01
2021-12-31143.72M CNY+23.9%2024-04-29, From 2021-01-01
2020-12-31115.98M CNY+7.0%2023-04-20, From 2020-01-01
2019-12-31108.34M CNY+46.8%2022-04-29, From 2019-01-01
2018-12-3173.81M CNYn/a2021-03-23, From 2018-01-01

Cost of Revenue at similar companies

Companies with the same SEC industry code (Services-Medical Laboratories), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCost of RevenueChange YoY
Burning Rock Biotech Ltd (BNR)2025-12-31136.65M CNY-10.9%
Concord Medical Services Holdings Ltd (CCM)2025-12-31434.69M CNY-6.1%

Compare BNR, CCM side by side · Screen every company in Services-Medical Laboratories ↗